Terms: = Pancreatic cancer AND CLTC, CLTCL2, 1213, ENSG00000141367, Q00610 AND Prognosis
11 results:
1. Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer.
Hotta T; Nariai Y; Kajitani N; Kadota K; Maruyama R; Tajima Y; Isobe T; Kamino H; Urano T
Biochimie; 2023 May; 208():160-169. PubMed ID: 36621663
[TBL] [Abstract] [Full Text] [Related]
2.
Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
[No Abstract] [Full Text] [Related]
3. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X
J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016
[TBL] [Abstract] [Full Text] [Related]
4. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
[TBL] [Abstract] [Full Text] [Related]
5. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
[TBL] [Abstract] [Full Text] [Related]
6. Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in pancreatic Adenocarcinoma: A Meta-Analysis.
Luo X; Yu B; Jiang N; Du Q; Ye X; Li H; Wang WQ; Zhai Q
Cancer Control; 2020; 27(1):1073274820977135. PubMed ID: 33269614
[TBL] [Abstract] [Full Text] [Related]
7. [Circulating tumor cells in pancreatic cancer : Results of morphological and molecular analyses and comparisons with the primary tumor].
Timme-Bronsert S; Bronsert P; Werner M; Kulemann B; Höppner J
Pathologe; 2018 Dec; 39(Suppl 2):311-314. PubMed ID: 30483865
[TBL] [Abstract] [Full Text] [Related]
8. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.
Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
Int J Oncol; 2014 Jun; 44(6):1820-30. PubMed ID: 24715238
[TBL] [Abstract] [Full Text] [Related]
10. [Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
Soriano-Izquierdo A; Adet AC; Gallego R; Miquel R; Castells A; Pellisé M; Nadal C; López-Boado MA; Piqué JM; Gascón P; Conill C; Bombí A; Fernández-Cruz L; Maurel J; Navarro S
Med Clin (Barc); 2009 Feb; 132(5):163-71. PubMed ID: 19211081
[TBL] [Abstract] [Full Text] [Related]
11. [Radiotherapy for bone metastases from hepatocellular carcinoma and pancreas cancer].
Harada H; Nishimura T; Kamata M; Asakura H; Zenda S; Takahashi M; Katagiri H; Takagi T
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1061-4. PubMed ID: 16912522
[TBL] [Abstract] [Full Text] [Related]
